TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02198469
Drug: Er:YAG AFL-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Study: NCT02198469
Drug: MAL-PDT
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Study: NCT02402049
Drug: Lachesis 30C
Normalized name: Lachesis muta venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02402049
Drug: Sepia 30C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02402049
Drug: Placebo Sepia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02402049
Drug: Placebo Nux vomica
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02402049
Drug: Placebo pulsatilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02402049
Drug: Placebo Folliculinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT04397510
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Heparin
Study: NCT01371799
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01371799
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg and 8mg Study drug
Study: NCT02417935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02469597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
Study: NCT00840177
Drug: pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,280 mg/day given orally on days 1-8
Study: NCT02898792
Drug: Targeted infusion of remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
Study: NCT01154985
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x Placebo capsules three times a day (TID) for 365 days
Study: NCT03633396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month
Study: NCT01557153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
Study: NCT00542139
Drug: Bupivocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular injection of 10ml of Bupivocaine
Study: NCT00537810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily
Study: NCT02853318
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00517634
Drug: SFC
Normalized name: SFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Study: NCT00517634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01156012
Drug: T2345
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of T2345
Study: NCT01156012
Drug: Prostaglandin
Normalized name: Prostaglandin
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop
Study: NCT00027404
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03345901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally BID - twice daily
Study: NCT02993133
Drug: Cellcept® in autoimmune bullous dermatoses
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
Study: NCT01026545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match 500 mg dose once daily for 10 days
Study: NCT01026545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match 750 mg dose once daily for 10 days
Study: NCT01026545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match 1100 mg dose once daily for 10 days
Study: NCT01026545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional cohort to match dose not greater than 1100 mg
Study: NCT04104399
Drug: XC101-D13H
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
Study: NCT04104399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied as matching capsules
Study: NCT02583399
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen, 10 mg/kg
Study: NCT00003389
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given IV
Study: NCT03000595
Drug: SAN007 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cream containing 5% East Indian sandalwood oil (EISO).
Study: NCT03000595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle cream
Study: NCT00003389
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT01116661
Drug: 5-Aminolevuline Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
Study: NCT00722046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 60 days (10 doses total)
Study: NCT03478540
Drug: Anti-Retroviral Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
Study: NCT01092572
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg per day orally for 12 weeks.
Study: NCT01092572
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 tablet once daily for 12 weeks
Study: NCT03112681
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Study: NCT01594749
Drug: Rescue Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03812198
Drug: LEO 32731 modified release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
Study: NCT03010917
Drug: Fish Oil with ethanol and placebo ethanol infusions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fish Oil with ethanol and placebo ethanol infusions
Study: NCT03010917
Drug: Placebo with ethanol and placebo ethanol infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with ethanol and placebo ethanol infusions
Study: NCT00387881
Drug: sumatriptan succinate / naproxen sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan 85mg / naproxen sodium 500mg
Study: NCT00387881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Treximet tablets
Study: NCT05621330
Drug: QL0911
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study: NCT03812198
Drug: LEO 32731 blend, hard capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study: NCT03812198
Drug: LEO 32731 API, hard capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study: NCT03812198
Drug: LEO 32731 gastro-resistant capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Study: NCT03812198
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Study: NCT05621330
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study: NCT00659412
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT00659412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular
Study: NCT05048914
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment of acute migraine attack
Study: NCT03658408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg sugar pill given orally 4 times a day
Study: NCT03990649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat matching placebo tablets
Study: NCT03793010
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Intra-articular injection
Study: NCT00003994
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00908050
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01444469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder
Study: NCT04366089
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Study: NCT00003684
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01989936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Study: NCT03356769
Drug: AED
Normalized name: Zaedoc
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintain the dosages and the drugs throughout the 3-month observation time
Study: NCT00714714
Drug: Tretinoin Gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin 0.1% topically applied daily in a split face model for two weeks
Study: NCT01131780
Drug: Ibuprofen + Pseudoephedrine Hydrochloride
Normalized name: ibuprofen / pseudoephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study: NCT01199640
Drug: MLN1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
Study: NCT00172003
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01841086
Drug: Anplag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study: NCT03356769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 5mg/Kg/d, once every day, 25mg per tablets
Study: NCT01058395
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
Study: NCT02714400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One piece of placebo before sleep
Study: NCT00656357
Drug: SYN117 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00656357
Drug: SYN117 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN117 80 mg
Study: NCT00656357
Drug: SYN117 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN117 160 mg
Study: NCT01179724
Drug: high dose proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
Study: NCT00003343
Drug: endocrine-modulating drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02219516
Drug: RDEA3170
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420823
Drug: Taurine 4g
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00223067
Drug: TAIZ
Normalized name: ALCOHOL 400 mL in 500 mL TOPICAL LIQUID [Miracle Power Hand Sanitaizer]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03259516
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
Study: NCT00700986
Drug: AZD9056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 800mg, one single administration
Study: NCT02319564
Drug: Beclomethasone and Salbutamol
Normalized name: salbutamol and beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02319564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00700986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT04559126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match EDP-297
Study: NCT02551536
Drug: Levocetrizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
Study: NCT03443141
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The applied dressing is a normal one without adding any product to it.
Study: NCT02017197
Drug: Marevan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
Study: NCT00979901
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet given once daily at bedtime for 2 weeks
Study: NCT01702974
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
Study: NCT03867214
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Study: NCT02228707
Drug: BIIB061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive BIIB061
Study: NCT01576887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT01005251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral,capsules, bid for 4 w
Study: NCT00810849
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
Study: NCT01117428
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.
Study: NCT02538458
Drug: 3 % hypertonic saline up to 72H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
Study: NCT02538458
Drug: 3 % hypertonic saline up to 24H
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group.
Study: NCT04236440
Drug: Placebo (A2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BAY2586116 (nasal spray administration)
Study: NCT04236440
Drug: BAY2586116 (B1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg BAY2586116 (nasal drops)
Study: NCT04236440
Drug: BAY2586116 (B3)
Normalized name: VITAMIN B3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
Study: NCT02798367
Drug: CBT-I plus Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Study: NCT02798367
Drug: CBT-I plus Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Study: NCT02061540
Drug: LUM001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM001 oral dose
Study: NCT01804413
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1-0.15 units/kg
Study: NCT02543801
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Study: NCT02543801
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Study: NCT01227252
Drug: LY2886721
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
Study: NCT01227252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules, daily for 14 days
Study: NCT00346216
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 to 200 mg twice daily, taken by mouth
Study: NCT00346216
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600 mg to 800 mg three times daily, taken by mouth
Study: NCT01608555
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: inhaled tobramycin 300 mg single dose OD for 28 days
Study: NCT00346216
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 375mg to 500 mg twice daily, taken by mouth
Study: NCT02499159
Drug: 0.25% standard bupivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.